1808 KB26 KB200520252022Avsec, DamjanMlinarič-Raščan, IrenaPodgornik, HelenaŠkerget, Matevžštevilka:5letnik:73str. 410-417ISSN:0014-8229COBISSID_HOST:132626435URN:URN:NBN:SI:doc-V5C321ICslSlovensko farmacevtsko društvoFarmacevtski vestnikakalabrutinibBTKibrutinibImunoterapijaKronična limfocitna levkemijaTarčno zdravljenje kronične limfocitne levkemije z zaviralci Brutonove tirozin kinaze| Targeting Bruton’s tyrosine kinase in chronic lymphocytic leukemia|Chronic lymphocytic leukemia (CLL) is characterised by the progressive accumulation of monoclonal B lymphocytes in the blood and lymphoid organs, and represents the most prevalent leukemia among adults in Slovenia. In the last decade, CLL treatment has undergone a radical change, as the standard of care chemoimmunotherapy has been replaced by small targeted molecules. The first among them are selective inhibitors of Bruton's tyrosine kinase (ibrutinib, acalabrutinib) and phosphatidylinositol 3- kinase (idelalisib, duvelisib), which target B-cell receptor signalling pathway of lymphocytes B. In this review, we present the development, significance and future of Bruton’s tyrosine kinase inhibitors in the targeted therapy of CLLKronična limfocitna levkemija (KLL) je bolezen kopičenja monoklonskih limfocitov B v krvi in limfatičnih organih in predstavlja najpogostejšo levkemijo pri odraslih v Sloveniji. V zadnjem desetletju je zdravljenje KLL doživelo korenito prenovo, saj so zlati standard kemoimunoterapijo nadomestile majhne tarčne molekule. Prvi v tej vrsti so zaviralci Brutonove tirozin kinaze (ibrutinib, akalabrutinib) in fosfatidilinozitol 3-kinaze (idelalizib, duvelizib), ki delujejo na receptorsko pot limfocitov B. V tem članku predstavljamo razvoj, pomen in prihodnost zaviralcev Brutonove tirozin kinaze pri tarčnem zdravljenju KLLTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo